Mối liên hệ giữa mức HER2/ErbB2 trong huyết thanh và bệnh động mạch vành: một nghiên cứu trường hợp - chứng

Wang M, Hu Y, Yu T, Ma X, Wei X, Wei Y. Pan-HER-targeted approach for cancer therapy: mechanisms, recent advances and clinical prospect. Cancer Lett. 2018;439:113–30. Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, Murthy RK, Rodon J, Piha-Paul SA. Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer. Clin Cancer Res. 2019;25:2033–41. Pernas S, Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol. 2019;11:1758835919833519. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 2002;110:669–72. Tse C, Gauchez AS, Jacot W, Lamy PJ. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev. 2012;38:133–42. Ray A. Tumor-linked HER2 expression: association with obesity and lipid-related microenvironment. Horm Mol Biol Clin Investig. 2017. https://doi.org/10.1515/hmbci-2017-0020. Fernandez-Real JM, Menendez JA, Fruhbeck G, Moreno-Navarrete JM, Vazquez-Martin A, Ricart W. Serum HER-2 concentration is associated with insulin resistance and decreases after weight loss. Nutr Metab (Lond). 2010;7:14. Memon AA, Bennet L, Zoller B, Wang X, Palmer K, Sundquist K, Sundquist J. Circulating human epidermal growth factor receptor 2 (HER2) is associated with hyperglycaemia and insulin resistance. J Diabetes. 2015;7:369–77. Muhammad IF, Borne Y, Bao X, Melander O, Orho-Melander M, Nilsson PM, Nilsson J, Engstrom G. Circulating HER2/ErbB2 levels are associated with increased incidence of diabetes: a population-based cohort study. Diabetes Care. 2019;42:1582–8. Sjaarda J, Gerstein HC, Yusuf S, Treleaven D, Walsh M, Mann JFE, Hess S, Pare G. Blood HER2 and uromodulin as causal mediators of CKD. J Am Soc Nephrol. 2018;29:1326–35. Hedhli N, Kalinowski A. K SR: cardiovascular effects of neuregulin-1/ErbB signaling: role in vascular signaling and angiogenesis. Curr Pharm Des. 2014;20:4899–905. Wu C, Gui C, Li L, Pang Y, Tang Z, Wei J. Expression and secretion of neuregulin-1 in cardiac microvascular endothelial cells treated with angiogenic factors. Exp Ther Med. 2018;15:3577–81. Beltowski J, Jazmroz-Wisniewska A. Transactivation of ErbB receptors by leptin in the cardiovascular system: mechanisms, consequences and target for therapy. Curr Pharm Des. 2014;20:616–24. Dreux AC, Lamb DJ, Modjtahedi H, Ferns GA. The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis. Atherosclerosis. 2006;186:38–53. Schreier B, Gekle M, Grossmann C. Role of epidermal growth factor receptor in vascular structure and function. Curr Opin Nephrol Hypertens. 2014;23:113–21. Wang L, Huang Z, Huang W, Chen X, Shan P, Zhong P, Khan Z, Wang J, Fang Q, Liang G, Wang Y. Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress. Sci Rep. 2017;8:45917. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S14–31. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12. Forrester SJ, Kawai T, O’Brien S, Thomas W, Harris RC, Eguchi S. Epidermal growth factor receptor transactivation: mechanisms, pathophysiology, and potential therapies in the cardiovascular system. Annu Rev Pharmacol Toxicol. 2016;56:627–53. Sanchez-Guerrero E, Jo SR, Chong BH, Khachigian LM. EGFR and the complexity of receptor crosstalk in the cardiovascular system. Curr Mol Med. 2013;13:3–12. Zeboudj L, Maitre M, Guyonnet L, Laurans L, Joffre J, Lemarie J, Bourcier S, Nour-Eldine W, Guerin C, Friard J, et al. Selective EGF-receptor inhibition in CD4(+) T cells induces anergy and limits atherosclerosis. J Am Coll Cardiol. 2018;71:160–72. Zeboudj L, Giraud A, Guyonnet L, Zhang Y, Laurans L, Esposito B, Vilar J, Chipont A, Papac-Milicevic N, Binder CJ, et al. Selective EGFR (epidermal growth factor receptor) deletion in myeloid cells limits atherosclerosis-brief report. Arterioscler Thromb Vasc Biol. 2018;38:114–9. Pagano E, Coso O, Calvo JC. Down-modulation of erbB2 activity is necessary but not enough in the differentiation of 3T3-L1 preadipocytes. J Cell Biochem. 2008;104:274–85. Myasoedova VA, Chistiakov DA, Grechko AV, Orekhov AN. Matrix metalloproteinases in pro-atherosclerotic arterial remodeling. J Mol Cell Cardiol. 2018;123:159–67. Bao W, Fu HJ, Jia LT, Zhang Y, Li W, Jin BQ, Yao LB, Chen SY, Yang AG. HER2-mediated upregulation of MMP-1 is involved in gastric cancer cell invasion. Arch Biochem Biophys. 2010;499:49–55. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared Risk Factors In Cardiovascular Disease And Cancer. Circulation. 2016;133:1104–14. Niederseer D, Stadlmayr A, Huber-Schonauer U, Ploderl M, Schmied C, Lederer D, Patsch W, Aigner E, Datz C. Cardiovascular risk and known coronary artery disease are associated with colorectal adenoma and advanced neoplasia. J Am Coll Cardiol. 2017;69:2348–50. Wang J, Zhou J, Wang Y, Yang C, Fu M, Zhang J, Han X, Li Z, Hu K, Ge J. Qiliqiangxin protects against anoxic injury in cardiac microvascular endothelial cells via NRG-1/ErbB-PI3K/Akt/mTOR pathway. J Cell Mol Med. 2017;21:1905–14. Kyotani Y, Ota H, Itaya-Hironaka A, Yamauchi A, Sakuramoto-Tsuchida S, Zhao J, Ozawa K, Nagayama K, Ito S, Takasawa S, et al. Intermittent hypoxia induces the proliferation of rat vascular smooth muscle cell with the increases in epidermal growth factor family and erbB2 receptor. Exp Cell Res. 2013;319:3042–50. Rohrbach S, Yan X, Weinberg EO, Hasan F, Bartunek J, Marchionni MA, Lorell BH. Neuregulin in cardiac hypertrophy in rats with aortic stenosis Differential expression of erbB2 and erbB4 receptors. Circulation. 1999;100:407–12. Rohrbach S, Niemann B, Silber RE, Holtz J. Neuregulin receptors erbB2 and erbB4 in failing human myocardium—depressed expression and attenuated activation. Basic Res Cardiol. 2005;100:240–9. Munk M, Memon AA, Goetze JP, Nielsen LB, Nexo E, Sorensen BS. Hypoxia changes the expression of the epidermal growth factor (EGF) system in human hearts and cultured cardiomyocytes. PLoS ONE. 2012;7:e40243. Whayne TF Jr, Saha SP. Genetic risk, adherence to a healthy lifestyle, and ischemic heart disease. Curr Cardiol Rep. 2019;21:1. Fujii H, Kono K, Nishi S. Characteristics of coronary artery disease in chronic kidney disease. Clin Exp Nephrol. 2019;23:725–32. Piche ME, Poirier P, Lemieux I, Despres JP. Overview of Epidemiology and contribution of obesity and body fat distribution to cardiovascular disease: an update. Prog Cardiovasc Dis. 2018;61:103–13. Khan S, Shukla S, Sinha S, Meeran SM. Role of adipokines and cytokines in obesity-associated breast cancer: therapeutic targets. Cytokine Growth Factor Rev. 2013;24:503–13. Vazquez-Martin A, Ortega-Delgado FJ, Fernandez-Real JM, Menendez JA. The tyrosine kinase receptor HER2 (erbB-2): from oncogenesis to adipogenesis. J Cell Biochem. 2008;105:1147–52. Cha Y, Kang Y, Moon A. HER2 induces expression of leptin in human breast epithelial cells. BMB Rep. 2012;45:719–23. Duchnowska R, Loibl S, Jassem J. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer Treat Rev. 2018;67:71–7. Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang YS. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer. 2018;17:36. Prada PO, Saad MJ. Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes. Expert Opin Investig Drugs. 2013;22:751–63. Melenhorst WB, Mulder GM, Xi Q, Hoenderop JG, Kimura K, Eguchi S, van Goor H. Epidermal growth factor receptor signaling in the kidney: key roles in physiology and disease. Hypertension. 2008;52:987–93. Jerusalem G, Lancellotti P, Kim SB. HER2 + breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Res Treat. 2019;177:237–50.